VERA:NSD-Vera Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 39.65

Change

0.00 (0.00)%

Market Cap

USD 2.07B

Volume

0.86M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 96.94B
MRNA Moderna Inc

N/A

USD 38.83B
BNTX BioNTech SE

N/A

USD 22.34B
ARGX argenx NV ADR

N/A

USD 22.28B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 19.03B
GMAB Genmab AS

N/A

USD 18.26B
RPRX Royalty Pharma Plc

N/A

USD 16.73B
BGNE BeiGene Ltd

N/A

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.35B

ETFs Containing VERA

IWC iShares Micro-Cap ETF 0.44 % 0.60 %

N/A

USD 0.87B
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

N/A

USD 9.89M
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

N/A

USD 0.13B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 157.80% 96% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 157.80% 96% N/A 98% N/A
Trailing 12 Months  
Capital Gain 496.24% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 496.24% 99% N/A 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 32.35% 80% B- 86% B+
Dividend Return 32.35% 80% B- 86% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 145.95% 17% F 10% F
Risk Adjusted Return 22.17% 77% C+ 59% D-
Market Capitalization 2.07B 89% A- 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector